#United States #Pleasanton #10x Genomics #Nasdaq TXG #Chromosome Biology

10x Genomics Financial Update for Q4 and 2025

10x Genomics, well-known for its pioneering contributions to single cell and spatial biology, recently released its financial results for the fourth quarter and the full year of 2025, alongside a cautious yet optimistic overview for the upcoming year of 2026.

Key Financial Metrics

During the fourth quarter of 2025, the company reported revenues of $166 million, marking a 1% increase compared to the same period in 2024. For the full year, the revenue totaled $642.8 million; yet when excluding one-time revenues from litigation settlements amounting to $44.1 million, the revenue represented a 2% decrease from 2024.

Gross Margin and Expenses

In terms of profitability, the gross margin stood at 68% for Q4 2025, up from 67% the previous year. This improvement was fueled by lower inventory write-downs and reduced royalty costs. Operating expenses for the fourth quarter fell significantly by 18%, totaling $132.6 million, attributed to decreased legal and personnel costs. In contrast, the operating loss was reported at $19.5 million, improved from a $49.8 million loss in Q4 of the prior year.

Yearly Performance

For the entire year, the company's gross margin was 69%, reflecting a strategic enhancement in license revenue and effective cost management. Operating expenses decreased as well, contributing to a yearly loss narrowing to $43.5 million from $182.6 million the previous year. Such results signal a notable recovery trajectory for the company.

Strategic Partnerships

10x Genomics is not just relying on numbers alone but is also moving forward with strategic partnerships. The recent collaborations with renowned institutions such as the Cancer Research Institute and PharosAI formalize their commitment to revolutionize cancer research using data-driven insights. Leveraging their Chromium and Xenium platforms, the company aims to create vast datasets enhancing drug discovery and diagnostics while addressing some of the biggest challenges in oncology.

Furthermore, a multi-year research initiative with the Dana-Farber Cancer Institute will focus on single-cell and spatial tumor analysis, targeting better diagnostic workflows to enhance patient care mechanisms.

Looking Ahead to 2026

As for the financial outlook for 2026, 10x Genomics anticipates revenues ranging from $600 million to $625 million, potentially reflecting stable growth despite the exclusion of the atypical revenue from prior litigation. The company aims to leverage advancements in AI and other growing sectors in translational research, aligning its innovative engines to meet the burgeoning demand in clinical opportunities.

CEO Serge Saxonov stated, "In 2025, our team executed with discipline through a challenging environment while continuing to strengthen the fundamentals of the business. As we look to 2026, I am excited by the expanding impact of our platforms, driven by new product innovations and strategic partnerships."

10x Genomics continues to assert itself as a leader in life sciences, committed not just to revenue growth but to making impactful advancements in health sciences through innovative technology. Investors and industry watchers will keenly await the outcomes of their upcoming ventures and product innovations that promise to shape the future of biomedicine.

For more details on the financial results, a recorded conference call is available on their website for replay, providing deeper insights into their future strategy and market position.

As we navigate through the evolving landscape of biomedicine, 10x Genomics stands as a luminary making substantial strides in understanding biological complexities, heralding a promising future for health solutions worldwide.